Ethicon has signed a cooperative development and commercialisation agreement, through its subsidiary NeuWave Medical, to work with Auris Health on robotically assisted bronchoscopic ablation of lung lesions to detect cancer.
Under the deal, NeuWave’s Flexible Microwave Ablation Technology will be combined with the Auris Monarch Platform for Robotic Bronchoscopy.
Go deeper with GlobalData
The companies plan to co-develop the integrated systems for robotic control, navigation and application of microwave ablation through bronchoscopes.
In addition, the agreement will involve optimisation of technology and procedure development.
Auris Health co-founder and CEO Frederic Moll said: “From the beginning, our vision has been to create a platform capable of enabling advanced diagnosis and therapy for a spectrum of disease, using the least-invasive approach.
“Through this collaboration, we believe we are taking a significant first step together toward making the goal of diagnosing and treating lung cancer, all through the body’s natural openings, an eventual reality.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company’s robotic Monarch Platform is intended to enable diagnostic and therapeutic bronchoscopy. It is designed to facilitate access to even small and hard-to-reach peripheral lung nodules with high precision.
Meanwhile, Ethicon’s NeuWave Flex is a flexible microwave ablation probe indicated for soft tissue ablation in percutaneous and open surgical procedures.
Based on the NeuWave percutaneous microwave ablation system, the probe can also be used for procedures that require the use of a lumen or scope to access the target tissue.
Both Monarch and NeuWave Flex have been cleared by the US Food and Drug Administration (FDA).
